On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

CytoDyn Inc. (CYDY) Contributing to the Evolution of HIV Treatments

HIV, a virus that attacks the immune system to the point of destroying it if not treated correctly, remains a global epidemic. According to Healthline (http://nnw.fm/i9ptS), more than 34 million people have died from the disease since it was first discovered in 1981. Currently, there is no confirmed cure for HIV, but getting treated is extremely important for those wanting to live a normal life once diagnosed.

Although anyone infected with the virus should begin antiretroviral treatment as soon as possible, no matter what ethnicity, age, or gender, the fact is that more than half of those infected with HIV are not currently receiving treatment, often because access to treatment is unavailable.

Treatment is important to stop the virus from spreading further. It has now been proven that HIV medication can reduce the chances of transmission to an HIV-negative partner by 96%. Not only this, the medication can also reduce chances of transmission to unborn children by 90%. The medication now developed is the best chance a person has for fighting HIV, and although there is no cure, many are able to live normal lives with the virus.

HIV treatments have evolved significantly over the years. Currently, the antiretroviral drugs approved by the U.S. Food and Drug Administration (FDA) are distinguished into four classes: Reverse Transcriptase (RT) inhibitors, Protease Inhibitors (PIs), entry or fusion inhibitors, and integrase inhibitors. To avoid the mutation of HIV cells and the resistance to single therapies, many doctors prescribe multidrug combination therapy.

CytoDyn Inc. (OTCQB: CYDY), a company committed to enhancing the lives of people with HIV, has been focusing its efforts on developing new therapies that provide flexibility and freedom to those living with the virus.

Its lead product, PRO 140, belongs to a new class of HIV therapeutics that is expected to protect healthy cells from the infection. The drug is different from many other therapies as it is not a synthetic drug and therefore has no visible issues with toxicity and side effects. In addition to the above, the studies undertaken on PRO 140 show that it does not induce the development of resistant viruses.

PRO 140 is currently one of the most advanced experimental monoclonal antibodies for HIV treatment, and CYDY believes that it will be beneficial to patients with complicating issues, such as those with single or multi-drug resistant viruses or those who have difficulty sticking to a daily drug regimen, as well as those who can’t tolerate the current therapies available due to side effects and toxicity or those with compromised organ function or complex medical requirements.

PRO 140 is currently undergoing two concurrent Phase 3 clinical trials.

For more information, visit www.CytoDyn.com

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office


Select A Month

Contact us: 212.418.1217